In a significant advancement for prostate cancer research, a first-of-its-kind study led by Emory researchers uncovered how ...

Pharmaceutical scientists, clinicians, nurses and pharmacists from the National University of Singapore (NUS) and National ...

Men on active surveillance for low- to intermediate-risk prostate cancer (PCa) have low risk for PCa-related mortality at a median follow-up of 18 years. However, a majority of men do progress and ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

Prostatype Genomics announces that previously communicated positive results from a Spanish multicentre study with Prostatype®, have now been confirmed in a scientific journal. The study included 93 pa ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

Research confirms that many men with nonmetastatic prostate cancer will not die of their disease once they received recommended treatment.

The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...

Prostate cancer is commonly diagnosed in men worldwide. Surgery, in the form of radical prostatectomy, is one of the main forms of treatment for men with localised prostate cancer. Prostatectomy has ...

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes.

Those with high-risk cancer were still twice as likely to die of other causes. Our data support adherence to guideline recommendations for treatment of prostate cancer.